Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin for relapsed or refractory AL amyloidosis
NL-OMON59241Phase 2Completed
- Sponsor
- European Myeloma Network B.V.
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin in light-chain amyloidosis, sponsored by European Myeloma Network B.V. Primary endpoint: CR/VGPR/low-dFLC response rate. Started Jun 2022; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NL-OMON59241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59241.